The purpose of the present study was to evaluate the efficacy, local tolerability, and safety of preservative-free tafluprost 0.0015% in a naturalistic setting using a prospective, observational design.
MATERIALS AND METHODS

Study Design
This study was a prospective, multicenter, 
RESULTS
Patient and Baseline Characteristics
In total, 1227 patients were excluded from the evaluation. These included patients for whom the time-period between the two visits was <4 or >12 weeks (n=808), patients with retrospectively collected data (n=349), patients with datasets with incomplete IOP readings (n=41), patients already treated at baseline with preservative-free tafluprost (n=17), and patients with different medical treatment for the right and left eye and with data that were not plausible (n=12). After the exclusion of these patients, 2123 patients of the initial dataset collected were eligible for the final evaluation. As shown in Table 1 for changing medication to preservative-free tafluprost (41.1%), followed by a lack of efficacy of the prior treatments (25.6%; Figure 1 ).
n.d.=no data. Reasons for changing therapy to preservative-free tafluprost 0.0015%, adding preservative-free tafluprost 0.0015% to an existing medical treatment regimen, or initiating therapy with preservative-free tafluprost 0.0015%. *Multiple entries.
In patients reporting a local intolerance at baseline, irritation was the most frequent symptom (36.6%) followed by hyperemia (27.3%), allergy (17.3%), and itching (16.8%; Figure 2 ).
Prior Glaucoma Medication
Prior to change of medication, patients used a variety of other glaucoma products (n=1673; 78.8%) or were naïve to treatment (n=450;
21.2%). The majority of patients were treated with a monotherapy (n=1133; 53.4%), most frequently with a prostaglandin analog (PGA; n=453; 21.3%) or a beta blocker (n=372; 17.5%).
Five-hundred and forty patients (25.4%) were treated with fixed-or nonfixed combinations (Table 2) .
Effect on IOP
In the overall patient population, IOP was 
Local Tolerability and Patient Satisfaction
Tolerability improved in the majority of patients after medication was changed to preservative-free tafluprost. At baseline, tolerability of the prior treatment was rated as "very good" and "good" by only 28.3% of the patients; 38.4% of patients rated the tolerability as "less satisfactory", and 18% as "not acceptable." Tolerability improved after the change of medication to preservativefree tafluprost; a total of 85.7% of patients rated the tolerability as "very good" and "good" improved: local tolerability was rated as "very good" and "good" by 39.6% and 46.3% of patients, respectively ( Figure 9 ). As shown in Figure 10 , at the final visit most patients (92.9%) and physicians (92.6%) were very satisfied or satisfied with using preservative-free tafluprost.
Adverse Events and Discontinuations
Only a few adverse events occurred during the treatment period. Therapy with preservativefree tafluprost was continued after the final visit by 2077 patients (97.8%). Eighteen 
Beta blockers n=59
CAIs n=25
Alpha-2-adrenergic receptor agonists n=10
Baseline
Final Visit Figure 6 . Mean intraocular pressure (IOP) (± SD) for the different monotherapy subgroups. *P<0.001. Figure 8 . Tolerability rating at baseline (prior medication) and at final visit (preservative-free tafluprost). n=1741 patients with ratings at baseline and at final visit. Figure 9 . Tolerability rating at baseline (prior PGA monotherapy) and at final visit (preservative-free tafluprost). n=447 patients. Details are given in Table 3 . 
DISCUSSION I n t h e p a t i e n t p o p u l a t i o n o f t h i
